First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value

Wim A. Wuyts1, Martin Kolb2, Susanne Stowasser3, Wibke Stansen3, John T. Huggins4, Ganesh Raghu5

Received: 30 March 2016/Accepted: 14 June 2016/Published online: 4 July 2016 © The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract In the Phase III INPULSIS® trials, 52 weeks’ treatment with nintedanib reduced decline in forced vital capacity (FVC) versus placebo in patients with idiopathic pulmonary fibrosis (IPF). Patients who completed the INPULSIS® trials could receive nintedanib in an open-label extension trial (INPULSIS®-ON). Patients with FVC <50 % predicted were excluded from INPULSIS®, but could participate in INPULSIS®-ON. In patients with baseline FVC ≤50 % and >50 % predicted at the start of INPULSIS®-ON, the absolute mean change in FVC from baseline to week 48 of INPULSIS®-ON was −62.3 and −87.9 mL, respectively (n = 24 and n = 558, respectively). No new safety signals were identified in INPULSIS®-ON compared with INPULSIS®. The decline in FVC in INPULSIS®-ON in both subgroups by baseline FVC % predicted was similar to that in INPULSIS®, suggesting that nintedanib may have a similar effect on disease progression in patients with advanced disease as in less advanced disease.

Keywords Interstitial lung diseases · Clinical trial · Disease progression · Tyrosine kinase

Introduction

Idiopathic pulmonary fibrosis (IPF) is a chronic form of interstitial pneumonia associated with worsening dyspnoea and progressive decline in lung function [1]. Measuring decline in forced vital capacity (FVC) is an established method for assessing disease progression in patients with IPF and is a predictor of mortality [2, 3].

Nintedanib, an intracellular inhibitor of tyrosine kinases [4, 5], is approved for the treatment of IPF in several countries and regions, including the US, Europe [6, 7] and Japan. In the most recent international clinical practice guideline, nintedanib received a conditional recommendation for use in the treatment of IPF, taking into account individual patients’ preferences [8].

The INPULSIS® trials were two replicate, randomised, placebo-controlled trials that assessed the efficacy and safety of 52 weeks’ treatment with nintedanib 150 mg twice daily (bid) in patients with IPF [9]. To be eligible to enter the INPULSIS® trials, patients had to be ≥40 years old and to have an FVC of ≥50 % predicted, diffusing capacity of the lung for carbon monoxide of 30–79 % predicted and forced expiratory volume in 1 s/FVC ratio of ≥0.7. In both trials, nintedanib slowed disease progression by reducing the annual rate of decline in FVC by approximately 50 % [9]. Diarrhoea was the most frequent adverse event in the nintedanib group, reported in 62.4 % of patients treated with nintedanib and 18.4 % on placebo [9].

Patients who completed the INPULSIS® trials were eligible to enter an open-label extension trial known as INPULSIS®-ON (NCT01619085), irrespective of their
FVC. Therefore, patients with FVC ≤50 % predicted could participate in INPULSIS®-ON. We assessed the decline in FVC and safety of nintedanib in INPULSIS®-ON in patients who started this open-label extension trial with FVC ≤50 % and >50 % predicted.

Methods

All patients who completed the 52-week treatment period and follow-up visit in an INPULSIS® trial were eligible to enter INPULSIS®-ON. All patients provided informed consent before entering INPULSIS®-ON. Per protocol, the off-treatment period between the end of INPULSIS® and start of INPULSIS®-ON could be 4–12 weeks. All patients in INPULSIS®-ON received open-label nintedanib. Patients who were receiving of nintedanib 150 mg bid or its matching placebo at the end of INPULSIS® received of nintedanib 150 mg bid in INPULSIS®-ON, while patients receiving nintedanib 100 mg bid or its matching placebo at the end of INPULSIS® could receive either nintedanib 100 or 150 mg bid in INPULSIS®-ON. The dose was decided based on discussion between the patient and investigator. As in the INPULSIS® trials, dose reduction to 100 mg bid or treatment interruption was allowed to manage adverse events [9]. The primary outcome was the incidence of adverse events. Change in FVC was a secondary outcome measure. FVC measurements were taken at the start of INPULSIS®-ON, at weeks 2, 4, 6, 12, 24, 36, 48, 64, every 16 weeks thereafter until the end-of-treatment visit, and at a follow-up visit planned for 28 days after the last intake of the study drug.

The first patient was enrolled into INPULSIS®-ON in July 2012. The trial is ongoing. We conducted a post hoc, exploratory subgroup analysis in patients with FVC ≤50 % and >50 % predicted at the start of INPULSIS®-ON based on an interim database lock in November 2014. The analyses were performed for all patients treated in INPULSIS®-ON, irrespective of the treatment they had received in INPULSIS®. Absolute and relative declines in FVC in INPULSIS®-ON were based on observed cases. Safety was assessed via reporting of adverse events according to the Medical Dictionary for Regulatory Activities (MedDRA). All analyses in INPULSIS®-ON were descriptive.

Results

A total of 1061 patients were treated in the INPULSIS® trials (638 with nintedanib, 423 with placebo) [9]. Of 807 patients who completed the INPULSIS® trials, 734 (91 %) patients were treated in INPULSIS®-ON (430 continuing nintedanib, 304 initiating nintedanib). Baseline FVC % predicted values were missing for three patients at the start of INPULSIS®-ON (one continuing nintedanib, two initiating nintedanib). At the start of INPULSIS®-ON, 41 patients had FVC ≤50 % predicted (23 continuing nintedanib, 18 initiating nintedanib) and 690 patients had FVC >50 % predicted (406 continuing nintedanib, 284 initiating nintedanib). Baseline characteristics at the start of INPULSIS® and INPULSIS®-ON are presented in Table 1. Mean (SD) exposure in INPULSIS®-ON was 16.7 (7.0) months. Mean (SD) duration of exposure in patients with FVC ≤50 % and >50 % predicted at the start of INPULSIS®-ON was 12.1 (8.6) and 17.0 (6.8) months, respectively.

FVC values from 24 patients with FVC ≤50 % predicted and 558 patients with FVC >50 % predicted at the start of INPULSIS®-ON were available at week 48. The absolute change in FVC from baseline of INPULSIS®-ON to week 48 of INPULSIS®-ON was of a similar magnitude in patients with FVC ≤50 % and >50 % predicted at the start of INPULSIS®-ON (mean [SEM] −62.3 [63.1] and −87.9 [10.0] mL, respectively) (Fig. 1a). Relative changes in FVC from baseline were also similar between subgroups (Fig. 1b). In both subgroups, the absolute change in FVC from baseline to week 48 of INPULSIS®-ON was of a similar magnitude to the absolute change from baseline of INPULSIS® to week 52 of INPULSIS® in patients treated with nintedanib in INPULSIS® (mean [SEM] −88.9 [11.6] mL).

A summary of the adverse events in INPULSIS® and INPULSIS®-ON is presented in Table 2. The most frequent adverse event in INPULSIS®-ON was diarrhoea, reported in 46.3 % and 64.6 % of patients with baseline FVC ≤50 % and >50 % predicted, respectively. Diarrhoea led to treatment discontinuation in 4.9 % and 5.4 % of patients in these subgroups, respectively. A higher proportion of patients with baseline FVC ≤50 % predicted compared with FVC >50 % predicted had adverse events of dyspnoea (24.4 % vs. 12.8 %) and progression of IPF (34.1 % vs. 15.1 %), which included disease worsening and acute exacerbations. Progression of IPF led to drug discontinuation in 17.1 % and 5.4 % of patients with baseline FVC ≤50 % and >50 % predicted, respectively. A higher proportion of patients with baseline FVC ≤50 % predicted than FVC >50 % predicted had serious adverse events (63.4 % vs. 39.3 %) and fatal adverse events (22.0 % vs. 9.6 %).

Discussion

In this interim analysis of data from INPULSIS®-ON, the open-label extension of the INPULSIS® trials, the absolute decline in FVC over 48 weeks was similar in patients with FVC ≤50 % and >50 % predicted at the start of
In both subgroups, the decline in FVC in INPULSIS®-ON was similar to the decline in FVC in patients treated with nintedanib in the preceding INPULSIS® trials. These results suggest that first, the effect of nintedanib on slowing disease progression is maintained beyond 52 weeks and, second, that patients with severely impaired FVC may receive the same benefit from nintedanib on reduction in FVC decline as patients with less severe impairment. In general, the adverse event profile was similar in both subgroups, with no new safety signals identified in INPULSIS®-ON compared to INPULSIS®, but as might be expected, serious adverse events and fatal adverse events were more common in patients with more advanced disease, as were adverse events of dyspnoea and disease progression.

These are the first data to be published on the effects of antifibrotic therapy in patients with FVC <50 % predicted. Patients with FVC <50 % predicted are usually excluded from clinical trials in IPF [9–13] as it is thought that it is too difficult to retain patients with severe lung function impairment in trials. However, studying this patient population is important, as patients with IPF and severely impaired lung function do not necessarily have poor lung function in other areas of the body and may still respond to therapy.

### Table 1 Baseline characteristics at start of INPULSIS® and INPULSIS®-ON trials

|                          | INPULSIS® | Placebo | INPULSIS-ON<sup>a</sup> | FVC ≤50 % predicted | FVC >50 % predicted |
|--------------------------|-----------|---------|--------------------------|----------------------|----------------------|
|                          | N (n = 638) | P (n = 423) | FVC ≤50 % predicted (n = 41) | FVC >50 % predicted (n = 690) |
| Age, years, mean (SD)    | 66.6 (8.1)  | 67.0 (7.9)  | 66.9 (8.3) | 67.1 (7.8)  |
| Male, n (%)              | 507 (79.5)  | 334 (79.0)  | 32 (78.0) | 554 (80.3)  |
| Race, n (%)              |            |         |                          |                      |
| White                    | 360 (56.4)  | 248 (58.6)  | 29 (70.7) | 401 (58.1)  |
| Asian                    | 194 (30.4)  | 128 (30.3)  | 8 (19.5)  | 207 (30.0)  |
| Black                    | 2 (0.3)     | 0 (0.0)     | 0 (0.0)   | 2 (0.3)     |
| Missing<sup>a</sup>      | 82 (12.9)   | 47 (11.1)   | 4 (9.8)   | 80 (11.6)   |
| Ex or current smoker, n (%) | 464 (72.7) | 301 (71.2)  | 26 (63.4) | 501 (72.6)  |
| Weight, kg, mean (SD)    | 79.2 (16.6) | 78.6 (16.5) | 78.8 (17.6) | 78.2 (16.1) |
| Body mass index, kg/m², mean (SD) | 28.1 (4.6) | 27.6 (4.6) | 27.1 (5.3) | 27.5 (4.4) |
| FVC, mL, mean (SD)       | 2714 (757)  | 2728 (810)  | 1602 (330) | 2683 (790)  |
| FVC, % predicted, mean (SD) | 79.7 (17.6) | 79.3 (18.2) | 45.0 (4.6) | 78.0 (17.9) |

<sup>a</sup> In France, regulation did not permit the collection of data on race
<sup>b</sup> n = 688 for subgroup of patients with FVC >50 % predicted at the start of INPULSIS®-ON
Table 2 Adverse events in INPULSIS® and INPULSIS®-ON

|                        | INPULSIS® (n = 638) | Placebo (n = 423) | INPULSIS-ON® (n = 41) | FVC ≤50 % predicted (n = 690) |
|------------------------|---------------------|-------------------|-----------------------|------------------------------|
| Any adverse event(s)   | 609 (95.5)          | 379 (89.6)        | 41 (100.0)            | 649 (94.1)                   |
| Most frequent adverse event(s)^
| Diarrhoea              | 398 (62.4)          | 78 (18.4)          | 19 (46.3)               | 446 (64.6)                   |
| Nausea                 | 156 (24.5)          | 28 (6.6)          | 7 (17.1)              | 111 (16.1)                   |
| Cough                  | 85 (13.3)           | 57 (13.5)         | 7 (17.1)              | 114 (16.5)                   |
| Nasopharyngitis        | 87 (13.6)           | 68 (16.1)         | 3 (7.3)               | 100 (14.5)                   |
| Bronchitis             | 67 (10.5)           | 45 (10.6)         | 4 (9.8)               | 97 (14.1)                    |
| Dyspnoea               | 49 (7.7)            | 48 (11.3)         | 10 (24.4)             | 88 (12.8)                    |
| Progression of IPF     | 64 (10.0)           | 61 (14.4)         | 14 (34.1)             | 104 (15.1)                   |
| Weight decreased       | 62 (9.7)            | 15 (3.5)          | 7 (17.1)              | 75 (10.9)                    |
| Severe adverse event(s)^c | 174 (27.3)       | 99 (23.4)         | 21 (51.2)             | 210 (30.4)                   |
| Serious adverse event(s)^d | 194 (30.4)       | 127 (30.0)        | 26 (63.4)             | 271 (39.3)                   |
| Fatal adverse event(s) | 37 (5.8)            | 31 (7.3)          | 9 (22.0)              | 66 (9.6)                     |
| Adverse event(s) leading to treatment discontinuation^e | 123 (19.3)       | 55 (13.0)         | 17 (41.5)             | 155 (22.5)                   |
| Diarrhoea              | 28 (4.4)            | 1 (0.2)           | 2 (4.9)               | 37 (5.4)                     |
| Progression of IPF     | 13 (2.0)            | 21 (5.0)          | 7 (17.1)              | 37 (5.4)                     |
| Nausea                 | 13 (2.0)            | 0 (0.0)           | 1 (2.4)               | 5 (0.7)                      |
| Fatigue                | 1 (0.2)             | 1 (0.2)           | 1 (2.4)               | 3 (0.4)                      |
| Weight decreased       | 6 (0.9)             | 1 (0.2)           | 1 (2.4)               | 6 (0.9)                      |
| Decreased appetite     | 9 (1.4)             | 1 (0.2)           | 0 (0.0)               | 3 (0.4)                      |

^
| a Adverse events reported in >12 % of patients in either treatment group in INPULSIS® and/or in the overall patient population in INPULSIS®-ON

| b Corresponds to the MedDRA term ‘IPF’, which included disease worsening and acute exacerbations of IPF

| c Events that were incapacitating or that caused an inability to work or to perform usual activities

| d Events that resulted in death, were immediately life threatening, resulted in persistent or clinically significant disability or incapacity, required or prolonged hospitalisation, were related to a congenital anomaly or birth defect, or were deemed serious for any other reason

| e Adverse events that led to permanent treatment discontinuation in ≥1 % of patients in the nintedanib or placebo group in INPULSIS® and/or in the overall patient population in INPULSIS®-ON

impaired FVC represent a patient group that require care in clinical practice [14]. Some physicians are already using antifibrotic drugs in patients with FVC <50 % predicted, based on regulatory authorities approving these drugs without restriction based on FVC [6, 7], but many physicians believe that the benefits of antifibrotic treatment would likely be reduced, and the side-effects worse, in patients with more advanced disease.

Subgroup analyses of pooled data from the INPULSIS® trials have demonstrated a consistent effect of nintedanib on FVC decline in patients with baseline FVC ≤70 % versus >70 % predicted, <80 % versus >80 % predicted and ≤90 % versus >90 % predicted [15–17], suggesting that nintedanib is effective in reducing progression of IPF irrespective of the stage of disease at which it is initiated. The latest international clinical practice guideline for IPF highlights that there is no evidence to suggest an optimal duration of therapy or a point at which therapy would no longer be efficacious [8].

As with all data from open-label extension trials, these results have limitations, including bias in the population who completed the randomised placebo-controlled trials and elected to continue in the open-label extension and the lack of a placebo comparator in the extension phase. Findings from this subgroup analysis should be interpreted with caution as the number of patients with FVC ≤50 % predicted at the start of INPULSIS®-ON was small.

In conclusion, in an interim analysis of data from the INPULSIS®-ON open-label extension trial, the decline in FVC in patients with baseline FVC ≤50 % and >50 % predicted was similar to that in patients treated with nintedanib in INPULSIS®, suggesting a similar benefit on disease progression, and no new safety signals were identified.
Acknowledgments. Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Julie Fleming and Wendy Morris of Fleishman-Hillard Group, Ltd, London, UK, during the preparation of this article. The authors were fully responsible for all content and editorial decisions, and were involved at all stages of manuscript development and have approved the final version.

Funding. The INPULSIS® and INPULSIS®-ON trials were funded by Boehringer Ingelheim.

Compliance with Ethical Standards.

Conflict of interest. The authors have reported to Lung the following conflicts of interest: WW reports receipt of grants paid to his institution from InterMune; and travel reimbursement for congresses from Boehringer Ingelheim. Roche and Bayer. MK reports receipt of grants and personal fees from Boehringer Ingelheim and Roche; personal fees from GlaxoSmithKline, Gilead, AstraZeneca, ProMetic and Genoa; and grants from Actelion, Respivert, the Canadian Institute for Health Research, and the Canadian Pulmonary Fibrosis Foundation. SS and WS are employees of Boehringer Ingelheim. JH reports receipts of grants from Boehringer Ingelheim (investigator in the INPULSIS® trials). GR reports receipt of personal fees and other from the following in his role as a consultant in IPF and ILD studies: Boehringer Ingelheim, FibroGen, Gilead, Veracyte, Promedior (anticipated fees), Roche-Genentech, Sanofi-Aventis, Biogen and UBC; personal fees from MedImmune; he also reports unpaid consultancy for IPF studies with Janssen.

Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References.

1. Raghu G, Collard HR, Egan JJ et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824
2. du Bois RM, Nathan SD, Richeldi L et al (2012) Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials. Am J Respir Crit Care Med 186:712–715
3. Karimi-Shah BA, Chowdhury BA (2015) Forced vital capacity in idiopathic pulmonary fibrosis–FDA review of pirfenidone and nintedanib. N Engl J Med 372:1189–1191
4. Hilberg F, Roth GI, Krssak M et al (2008) BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68:4774–4782
5. Wollin L, Wex E, Pautsch A et al (2015) Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 45:1434–1445
6. Boehringer Ingelheim Pharmaceuticals, Inc. (2016) OFEV™ (nintedanib) prescribing information. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt &folderPaths=Prescribing+Information/Pls/Ofev/ofev.pdf. Accessed 25 May 2016
7. Boehringer Ingelheim (2016) OFEV (nintedanib) Summary of Product Characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003821/WC500182474.pdf. Accessed 17 March 2016
8. Raghu G, Rochwerg B, Zhang Y et al (2015) An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 192:e5–e19
9. Richeldi L, du Bois RM, Raghu G et al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370:2071–2082
10. Noble PW, Albera C, Bradford WZ et al (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377:1760–1769
11. Richeldi L, Costabel U, Selman M et al (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365:1079–1087
12. King TE Jr, Bradford WZ, Castro-Bernardini S et al (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370:2083–2092
13. Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez FJ, de Andrade JA et al (2014) Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 370:2093–2101
14. Harari S, Caminati A (2015) Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences. Eur Respir Rev 24:420–427
15. Costabel U, Inoue Y, Richeldi L et al (2016) Efficacy of nintedanib in idiopathic pulmonary fibrosis across pre-specified subgroups in INPULSIS®. Am J Respir Crit Care Med 193:178–185
16. Maher TM, Flaherty KR, Noble PW et al (2015) Effect of baseline FVC on lung function decline with nintedanib in patients with IPF. Eur Respir J 46(Suppl 59):OA4499
17. Kolb M, Richeldi L, Kimura T et al (2015) Effect of baseline FVC on decline in lung function with nintedanib in patients with IPF: results from the INPULSIS® trials. Am J Respir Crit Care Med 191:A1021